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Pharmacological Modulation of the Mitochondrial
Electron Transport Chain in Paclitaxel-Induced Painful
Peripheral Neuropathy
Lisa A. Griffiths and Sarah J. L. Flatters
Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King’s College London,
London, United Kingdom.
Abstract: Paclitaxel is an effective first-line chemotherapeutic with the major dose-limiting side
effect of painful neuropathy. Mitochondrial dysfunction and oxidative stress have been impli-
cated in paclitaxel-induced painful neuropathy. Here we show the effects of pharmacological
modulation of mitochondrial sites that produce reactive oxygen species using systemic rotenone
(complex I inhibitor) or antimycin A (complex III inhibitor) on the maintenance and development
of paclitaxel-induced mechanical hypersensitivity in adult male Sprague Dawley rats. The maxi-
mally tolerated dose (5 mg/kg) of rotenone inhibited established paclitaxel-induced mechanical
hypersensitivity. However, some of these inhibitory effects coincided with decreased motor coor-
dination; 3 mg/kg rotenone also significantly attenuated established paclitaxel-induced mechan-
ical hypersensitivity without any motor impairment. The maximally tolerated dose (.6 mg/kg) of
antimycin A reversed established paclitaxel-induced mechanical hypersensitivity without any mo-
tor impairment. Seven daily doses of systemic rotenone or antimycin A were given either after
paclitaxel administration or before and during paclitaxel administration. Rotenone had no signif-
icant effect on the development of paclitaxel-induced mechanical hypersensitivity. However, anti-
mycin A significantly inhibited the development of paclitaxel-induced mechanical hypersensitivity
when given before and during paclitaxel administration but had no effect when given after
paclitaxel administration. These studies provide further evidence of paclitaxel-evoked mitochon-
drial dysfunction in vivo, suggesting that complex III activity is instrumental in paclitaxel-induced
pain.
Perspective: This study provides further in vivo evidence that mitochondrial dysfunction is a key
contributor to the development and maintenance of chemotherapy-induced painful neuropathy.
This work also indicates that selective modulation of the electron transport chain can induce antino-
ciceptive effects in a preclinical model of paclitaxel-induced pain.
ª 2015 The Authors. Published by Elsevier Inc. on behalf of the American Pain Society. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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aclitaxel, a taxane-derived chemotherapeutic, is a
first-line treatment for solid tumors, particularly
breast and ovarian carcinomas. Its primary anti-
cancer action occurs via disruption of the mitotic spindle
and microtubule dynamics resulting in cycle arrest and
apoptosis.13,17,37 The major dose-limiting adverse effect
of paclitaxel treatment is a peripheral, predominantly
sensory, neuropathy that occurs in a stocking-and-glove
distribution.28,38 Patients typically report numbness,
tingling, spontaneous pain, and evoked pain to
mechanical and cold stimuli.3,6,12 The severity of
symptoms depends on various factors, including
cumulative dose33 and the presence of comorbidities
associated with increased risk of neuropathy, such as dia-
betes.5 Unfortunately, patients may continue to
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experience symptoms for months or years after cessation
of paclitaxel.3,6,45 Treatment options for chemotherapy-
induced painful peripheral neuropathies are very
limited. Most analgesics with established efficacy in
neuropathic pain are not effective in patients with
chemotherapy-induced painful peripheral neuropa-
thy.19,20,34,35 However, duloxetine was recently
reported to significantly reduce pain scores compared
with placebo in this patient population.41 Differential
sensitivity of chemotherapy-induced pain to otherwise
effective analgesics could potentially relate to differ-
ences in the causal mechanisms of neuropathic pain
states.
Paclitaxel-induced painful peripheral neuropathy has
been accurately modeled in rats using low doses of sys-
temic paclitaxel on alternate days to mimic cycles of
chemotherapy, which evokes hypersensitivity tomechan-
ical and cold stimuli.8,9 In this translational rat model of
paclitaxel-induced painful peripheral neuropathy,
increased incidence of atypical (swollen and vacuolated)
mitochondria was observed in peripheral sensory nerves
in the absence of mid-axonal degeneration.10 Further-
more, these atypical changes in neuronal mitochondria
correlate with the presence of paclitaxel-induced me-
chanical hypersensitivity,10 suggesting a causal role of
mitochondrial dysfunction in paclitaxel-induced painful
peripheral neuropathy. The presence of swollen and
vacuolated mitochondria indicates mitochondrial
dysfunction but does not indicate the nature of themito-
chondrial dysfunction given the multiple functions that
mitochondria perform.Mitochondria are amajor cellular
source of reactive oxygen species (ROS).29 ROS are free
radicals and reactive molecules that are derived from
molecular oxygen; examples include superoxide, hydrox-
yl radical, nitric oxide, and hydrogen peroxide. ROS can
react with many different substrates and with each
other; for example superoxide and nitric oxide react to
form peroxynitrite.30 Several studies have provided
evidence that ROS are involved in nerve injury–induced
and inflammatory pain.16,21,22,26,31,39,40 Moreover,
systemic administration of a nonspecific ROS scavenger
prevented the development of paclitaxel-induced me-
chanical hypersensitivity and reversed established
paclitaxel-induced mechanical and cold hypersensitiv-
ities.8,23 In addition, peroxynitrite decomposition
catalysts were reported to prevent and reverse
paclitaxel-induced mechanical hypersensitivity.7
Embedded within the inner mitochondrial membrane
are the protein complexes of the electron transport
chain, which are key components of oxidative phosphor-
ylation. Complex I44 and complex III43 are known sources
of ROS as a consequence of electron transfer. In patho-
logical states, the amount of ROS produced at these com-
plexes may increase beyond the antioxidant capacity of
the cell, resulting in oxidative stress. In our previous
study,8 we established the importance of ROS in vivo to
the development and maintenance of paclitaxel-
induced pain. Here, we have used selective pharmaco-
logical inhibitors of complex I (rotenone) and complex
III (antimycin A) to assess the effects of modulation of
the electron transport chain on the development and
maintenance of paclitaxel-induced painful peripheral
neuropathy. This work was previously presented in
abstract form.15
Methods
Animals
Adult male Sprague Dawley rats (starting weight
170–220 g; Harlan, Oxford, UK) were housed in groups
of 4 in plastic cages with sawdust bedding and environ-
mental enrichment materials, in a room only containing
rats. Bedding/cages were changed twice a week. Artifi-
cial light was provided on a 12-hour light-dark cycle
(lights on at 7 AM), and standard rat chow and water
were available ad libitum. Rats were habituated to the
testing environment for approximately 30 minutes on 3
separate occasions before baselinemechanical sensitivity
testing. Throughout all studies, rats were routinely
checked visually and weighed to ensure good health.
Health status before treatment was normal. All studies
were carried out in accordance with the UK Animals (Sci-
entific Procedures) Act (1986) and the ethical guidelines
issued by the International Association for the Study of
Pain.48
Assessment of Mechanical
Hypersensitivity
Rats were placed in an elevated apparatus consisting
of a wire-rung floor (spaced 8 mm apart), with each rat
separated by acrylic dividers (box dimensions
15 cm  16 cm  21 cm). Rats were allowed to acclima-
tize for 5 to 10 minutes. Testing commenced when the
animal was alert, settled, and weight-bearing equally
on all 4 paws. Von Frey filaments (Touch-Test Sensory
Evaluators, Linton Instrumentation, Norfolk, UK) of 4 g,
8 g, and 15 g bending forces were used in ascending
order of force. The filament was applied 5 times, in a
pseudorandom order, to the midplantar surface of each
hind paw, and each stimulus was held for 5 seconds.
The number of withdrawal responses for the 2 hind
paws were added together to give a score out of a
maximum of 10 withdrawals for each of the 3 von Frey
filaments. After habituation, 3 baseline measurements
ofmechanical sensitivity were taken before commencing
paclitaxel administration. Mechanical sensitivity was as-
sessed in the morning (8–11 AM).
Assessment of Motor Coordination
Motor coordination was assessed using an acceler-
ating Rota-rod (Ugo-Basile, Monvalle, Varese, Italy)
and catalepsy ring apparatus. The initial speed of the
Rota-rod was set at 5 rotations per minute (rpm) and
gradually increased from 5 to 40 rpm over 5 minutes
(300 seconds). The latency (in seconds) of the rats falling
off the Rota-rod onto the sensor platform was recorded.
Two or 3 training sessions were given (until all rats were
able to remain on the apparatus for 180 seconds or
more), followed by 1 baseline measurement before
commencing paclitaxel administration. All rats were
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tested at a similar time on each testing day (late morn-
ing, after testing for mechanical hypersensitivity). After
testing on the accelerating Rota-rod, catalepsy was as-
sessed using a ring apparatus (Fisherbrand, Loughbor-
ough, UK) as previously described.32 Each rat was
placed onto a horizontal steel ring, 12.5 cm in diameter,
and elevated approximately 9 cm above a platform. The
rat was positioned so that all 4 paws were gripping the
ring. A timer was stopped when the rat put at least 1
paw on the platform. The time spent immobile on the
ring, expressed as latency (seconds), was noted. Two
training sessions were given, followed by one baseline
measurement before commencing paclitaxel adminis-
tration.
Drug Administration
Paclitaxel
After habituation and baseline mechanical sensitivity
testing, rats received intraperitoneal (i.p.) injections of
2 mg/kg paclitaxel on 4 alternate days (days 0, 2, 4, and
6) as previously described.8-11 Paclitaxel concentration
for solution for infusion (6 mg/mL; CP Pharmaceuticals
Ltd/Actavis, Devon, UK) was diluted with .9% sterile
saline (Fresenius Kabi, Manor Park, UK) and injected at
2 mg/mL/kg body weight. Injections were performed in
the morning, and rats were immediately returned to
their home cages afterward.
Inhibitors of Complex I (Rotenone) and Com-
plex III (Antimycin A)
Rotenone and antimycin A (Sigma-Aldrich, Dorset, UK)
were dissolved inMiglyol 812N (Azelis, Hertford, UK) and
sonicated for 15 to 60 minutes resulting in clear colorless
solutions. Rotenone or antimycin Awas administered i.p.
(for systemic exposure) at 1 mL/kg body weight in either
treatment (see section on Effects of Complex I/III Inhibi-
tion on Established Paclitaxel-Induced Mechanical Hy-
persensitivity) or prophylactic dosing paradigms (see
section on Effects of Complex I/III Inhibition on theDevel-
opment of Paclitaxel-Induced Mechanical Hypersensitiv-
ity) to test if the inhibition of complex I or III could inhibit
established paclitaxel-induced pain or prevent the devel-
opment of paclitaxel-induced pain, respectively. Unless
otherwise stated, injections of complex inhibitors were
performed in the morning, and rats were immediately
returned to their home cages afterward. In initial studies,
1 mg/kg and 2 mg/kg rotenone were used. The choice of
these doses was based on reports of repeated dosing
with 3 mg/kg rotenone to model Parkinson disease.4 In
our pilot studies of drug tolerability, we found 5 mg/kg
rotenone was the maximally tolerated dose when given
as a single bolus i.p. injection in naive rats. The median
lethal dose of antimycin A in adult rats was previously
shown to be .81 mg/kg.36 In our pilot studies, we found
.6 mg/kg antimycin A was the maximally tolerated dose
when given as a single bolus i.p. injection in naive rats.
Because of toxicity concerns with repeated daily dosing,
2 mg/kg rotenone and .4 mg/kg antimycin A were the
maximum doses used in prophylactic studies.
Blinding and Randomization
In all studies, rats were split into groups of equal
mechanical sensitivity based on their average baseline
or post-paclitaxel responses. Drug treatments were ran-
domizedwithin the groups of rats being tested in a given
session. Therefore, a concurrent vehicle-treated group
was present throughout all experiments to minimize
extraneous variables on behavioral responses such as
time of day. All behavioral testing was carried out by
a single experimenter (L.A.G.), who was blinded to the
treatment group. For studies on established mechanical
hypersensitivity, drug/vehicle administration was per-
formed by another scientist (S.J.L.F.). For prophylactic
studies, the experimenter (L.A.G.) carried out all injec-
tions but the drug vials were relabeled by a third party
before drug administration. In the prophylactic studies,
there was a period of overlap between drug administra-
tion and behavioral testing. During this period, the cages
were relabeled by a third party before behavioral
testing, which further disguised the identity of the treat-
ment received by each rat during testing. When drug
administration was complete, the rats were renumbered
by a third party for the remaining duration of the exper-
iment. At the end of the studies, the identity of the treat-
ment each rat received was revealed for data analysis.
Sample size was determined based on extensive previous
studies using rats with paclitaxel-induced painful
neuropathy.8-11
Effects of Complex I/III Inhibition on
Established Paclitaxel-Induced
Mechanical Hypersensitivity
The effects of single bolus doses of rotenone or anti-
mycin A on established paclitaxel-induced mechanical
hypersensitivity were assessed in separate experiments.
On day 26/28 after paclitaxel initiation, after assessment
of mechanical sensitivity, rats received an i.p. injection
of either rotenone (1 mg/kg or 2 mg/kg) or vehicle
(n = 8 per group). Neither 1mg/kg nor 2mg/kg rotenone
had any effect on mechanical hypersensitivity at 1, 3, or
24 hours after injection (data not shown). In another
experiment, on day 28/29 after paclitaxel initiation, af-
ter assessment of mechanical sensitivity, rats received
an i.p. injection of either rotenone (3 mg/kg or 5 mg/
kg, n = 7) or vehicle (n = 6). The effects of these higher
doses of rotenonewere assessed at 1, 3, and 24 hours af-
ter injection. At the 24-hour time point, 2 rats were
obviously sedated and were excluded from testing. At
the end of the experiment, these 2 rats were found to
have received 5 mg/kg rotenone. On day 33 after pacli-
taxel initiation, after assessment of mechanical sensi-
tivity, rats received an i.p. injection of either antimycin
A (.2 mg/kg or .4 mg/kg) or vehicle (n = 8 per group).
Neither .2 mg/kg nor .4 mg/kg antimycin A had any ef-
fect on mechanical hypersensitivity at 1, 3, and 24 hours
after injection (data not shown). In a further experi-
ment, also on day 33 after paclitaxel initiation, after
assessment of mechanical sensitivity, rats received an
i.p. injection of either .6 mg/kg antimycin A or vehicle
(n = 8 per group). The effects of this higher dose of
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antimycin A were assessed at 1, 3, and 24 hours after
injection.
Effects of Complex I/III Inhibition on the
Development of Paclitaxel-Induced
Mechanical Hypersensitivity
The effects of repeated dosing of rotenone or
antimycin A on the development of paclitaxel-induced
mechanical hypersensitivity were assessed in separate
experiments using 2 different prophylactic dosing para-
digms. Complex inhibitors or vehicle were administered
once daily for 7 days to rats either after paclitaxel treat-
ment on days 7 to 13, or before and during paclitaxel
treatment on days 1 to 5 (paclitaxel was given on
days 0, 2, 4, and 6, as described earlier).
Prophylactic Complex I/III Inhibition (Days 7
to 13)
After the final baseline test for mechanical sensitivity
(day 0), all rats received paclitaxel as described earlier.
On day 7, after assessment of mechanical sensitivity, rats
were allocated into 3 groups of equal sensitivity (n = 8
per group). In an experiment, rats then received either
rotenone (1 mg/kg or 2 mg/kg i.p.) or vehicle once daily
on days 7 to 13. In a similar separate experiment, on day
7, rats then received either antimycin A (.2 mg/kg or
.4 mg/kg i.p.) or vehicle once daily on days 7 to 13. During
this experiment, 1 rat died part way through the drug
administration protocol. In addition, an error in blinding
and randomization procedures occurred, so 8 rats that
had been incorrectly assigned were removed from the
experiment. The antimycin A (.2 mg/kg or .4 mg/kg i.p.)/
vehicle experiment was repeated at a later date (n = 4
per group) and all 12 animals survived. Thus, we pooled
the data from both blinded randomized experiments re-
sulting in n = 9 per group. In both prophylactic studies
with complex inhibitor/vehicle administration on days 7
to 13, rats were assessed for the development of mechan-
ical hypersensitivity in the morning on days 10, 12, 14, 18,
23, 28, 33, 38, and 44.
Prophylactic Complex I/III Inhibition (Days 1
to 5)
Only the highest doses of rotenone and antimycin A
used in the prophylactic dosing paradigm (days 7–13)
were used for these experiments to minimize animal us-
age in accordance with the 3 Rs principles of animal
research (Replacement, Reduction, and Refinement). Af-
ter the final baseline assessment ofmechanical sensitivity
(day1), rats were split into 2 groups of equal sensitivity
(n = 8 per group). In 1 experiment, rats received either i.p.
2 mg/kg rotenone or vehicle. In a similar separate exper-
iment, on day 1, rats then received either i.p. .4 mg/kg
antimycin A or vehicle. In both experiments, the
following morning (day 0) after the first injection of
complex inhibitor or vehicle, rats were assessed for the
acute effects of complex I/III inhibition on mechanical
sensitivity. Rats were then injected with 2 mg/kg pacli-
taxel, and 5 to 6 hours later the second injection of com-
plex I/III inhibitor was given. Rats were injected once
daily with complex I/III inhibitor or vehicle on days 1
to 5 and paclitaxel on days 0, 2, 4, and 6. When complex
inhibitor/vehicle and paclitaxel were administered on
the same day, paclitaxel was injected between 11 AM
and 12 PM, followed by complex inhibitor/vehicle admin-
istration between 5 PM and 6 PM. On themorning of day 6,
after the last injection of complex inhibitor/vehicle and
before paclitaxel administration, rats were assessed for
mechanical hypersensitivity to examine any effects of cu-
mulative dosing. In the initial antimycin A/vehicle exper-
iment, 5 rats died after the last injection on day 5. After
unblinding at the end of the experiment, all 5 rats were
found to have received antimycin A. The reason for these
deaths is unclear, although it may have been due to a
lower starting weight (208–224 g) and, compared with
vehicle-treated rats, minimal weight gain during the
period of antimycin A administration. The .4 mg/kg anti-
mycin A and vehicle experiment was repeated at a later
date (n = 6 per group) with slightly heavier rats (240–
255 g), and all 12 animals survived. Thus, we pooled
the data from both blinded randomized experiments re-
sulting in n = 9 for antimycin A and n = 14 for vehicle. In
both prophylactic studies with complex inhibitor/vehicle
administration on days 1 to 5, rats were also assessed
for the development of mechanical hypersensitivity in
the morning on days 10, 14, 18, 23, 28, 33, 38, and 44.
Effects of Complex I/III Inhibition on
Motor Coordination
Rotenone is used experimentally to generate motor
deficits modeling Parkinson disease4 in a dosing
regimen of up to 3 mg/kg/day for up to 60 days, with
motor deficits appearing after 6 days. Therefore, we
tested the effects of complex inhibitors on motor coor-
dination to assess if observed drug effects on paclitaxel-
induced mechanical hypersensitivity were due to sen-
sory changes alone. Naive rats, weight-matched to
those in established pain studies (300–330 g), received
i.p. 5 mg/kg rotenone, .6 mg/kg antimycin A, or vehicle
(n = 6 per group), and in a separate study either i.p.
3 mg/kg rotenone or vehicle (n = 6 per group). Motor
coordination using accelerating Rota-rod and catalepsy
ring (see section on Assessment of Motor Coordination)
was then assessed at 1, 3, and 24 hours after injection of
complex inhibitor/vehicle. There was no difference in
responses between groups before receiving the injec-
tion of complex inhibitor/vehicle, so these data were
pooled for baseline responses. The effects of repeated
daily dosing for 7 days of rotenone and antimycin A
on motor coordination were also assessed. During the
prophylactic complex I/III inhibition experiments (see
section on Effects of Complex I/III Inhibition on the
Development of Paclitaxel-Induced Mechanical Hyper-
sensitivity), performance on the Rota-rod and catalepsy
ring was assessed on days 1 (baseline), 0, 6, 14, 23, 33,
and 44 after testing for mechanical hypersensitivity. As
previously described, paclitaxel-treated rats received
i.p. 2 mg/kg rotenone or vehicle (n = 8 per group),
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and in a separate experiment either i.p. .4 mg/kg anti-
mycin A or vehicle (n = 9–14 per group). For ease of
illustration, we pooled the vehicle group data from
both blinded randomized experiments, resulting in
n = 8 for rotenone, n = 9 for antimycin A, and n = 22
for vehicle. For statistical comparisons between the ef-
fects of rotenone or antimycin A administration and
vehicle treatment, data from the concurrent vehicle-
treated group in each experiment were used.
Statistics
All analyses were carried out using GraphPad Prism 6
or GraphPad InStat 3 for Windows (GraphPad Software,
Inc, La Jolla, CA). To assess for the presence of
paclitaxel-induced mechanical hypersensitivity in estab-
lished pain studies, a paired 1-tailed t-test was carried
out. For established pain studies with 3 treatment
groups, a 1-way analysis of variance (ANOVA) with Dun-
nett post hoc comparison with vehicle control at each
time point was carried out. For established pain studies
with 2 treatment groups, unpaired 2-tailed t-tests with
Bonferroni correction were used to compare the effects
of complex inhibition with vehicle treatment. Paired 2-
tailed t-tests were used to compare responses after
complex inhibition to pre-paclitaxel baseline responses
to assess if established paclitaxel-induced mechanical
hypersensitivity had been reversed and to test if com-
plex inhibition significantly attenuated responses
beyond pre-paclitaxel response levels. One-way
repeated measures (RM) ANOVA with Dunnett post
hoc comparison with pre-paclitaxel baseline responses
was used to test for significant development of
paclitaxel-induced mechanical hypersensitivity. To assess
the acute effects of complex inhibition on mechanical
hypersensitivity (prophylactic paradigm days 1 to 5),
paired 1-tailed t-tests were performed comparing day
1 with baseline responses. The effect of complex inhi-
bition on the development of paclitaxel-induced me-
chanical hypersensitivity was also assessed using an
area under the curve analysis on data collected from
day 10 onward, with unpaired 2-tailed t-tests to
compare vehicle with drug treatment group. To assess
the acute effects of complex inhibition on motor coor-
dination of naive rats, a 1-way ANOVA with Dunnett
post hoc comparison with vehicle control at each time
point was performed when there were 3 treatment
groups, and unpaired 2-tailed t-tests with Bonferroni
correction were used to compare the effects of complex
inhibition with vehicle treatment in experiments with 2
groups (data not shown). To assess the effects of multi-
ple injections of complex inhibitors on motor coordina-
tion in paclitaxel-treated rats, 2-way repeated measures
ANOVA with Bonferroni post hoc comparison with
vehicle control at each time point was performed. All
animals were used in the statistical analyses unless
otherwise stated. Data are presented as
mean 6 standard error of the mean (SEM). Statistical
significance was accepted at P < .05. No further distinc-
tion has been made when P < .01 or P < .001 and is de-
noted on figures as P < .05.
Results
Effect of Complex I Inhibition on
Established Paclitaxel-Induced
Mechanical Hypersensitivity
Four systemic injections of 2 mg/kg paclitaxel resulted
in a robustmechanical hypersensitivity on day 28/29 after
paclitaxel initiation (Fig 1, P < .05, 1-tailed paired t-tests)
as previously described.8-10 Administration of a single
dose of either 1 or 2 mg/kg rotenone had no effect on
paclitaxel-induced mechanical hypersensitivity at 1, 3,
or 24 hours after administration (data not shown).
Three mg/kg rotenone significantly attenuated re-
sponses to von Frey 15 g at 3 hours after administration
compared with the concurrent vehicle-treated group
(Fig 1C, P < .05, 1-way ANOVA with Dunnett post hoc
analysis). Some inhibitory effects of 3 mg/kg rotenone
were also observed at 1 and 3 hours after administration
with von Frey 15 g and von Frey 8 g responses, but these
were not statistically significant (Figs 1B and 1C). One
hour after 5 mg/kg rotenone administration, responses
to von Frey 8 g and 15 g were significantly inhibited
compared with the concurrent vehicle-treated group
(Figs 1B and 1C, P < .05 1-way ANOVA with Dunnett
post hoc analysis). Three hours after 5 mg/kg rotenone
administration, responses to all von Freys were pro-
foundly inhibited compared with the concurrent
vehicle-treated group (Fig 1, P < .05, 1-way ANOVA
with Dunnett post hoc analysis). The inhibition by
5 mg/kg rotenone at this 3-hour time point was a
complete reversal of paclitaxel-induced mechanical hy-
persensitivity but also a significant inhibition beyond
pre-paclitaxel baseline responses (P < .05, 2-tailed paired
t-tests). Twenty-four hours after rotenone administra-
tion, the observed inhibitory effects of rotenone had
largely disappeared. There was no difference between
rotenone-treated groups and the vehicle group,
with the exception of 5 mg/kg rotenone on von Frey 15
g responses.
Effect of Complex III Inhibition on
Established Mechanical Hypersensitivity
We have consistently found with multiple rat cohorts
that 4 systemic injections of 2 mg/kg paclitaxel on alter-
nate days (0, 2, 4, and 6) evokes a marked long-lasting
mechanical hypersensitivity, which reaches its maximum
around day 27, remains high for several weeks, and
finally resolves approximately 6 months after paclitaxel
initiation (data not shown). Thus, as expected, a marked
paclitaxel-induced mechanical hypersensitivity was
observed at day 33 after paclitaxel initiation (Fig 2,
P < .05, 1-tailed paired t-tests) that was of similar magni-
tude to that observed at day 28/29 (Fig 1).
Administration of a single dose of either .2 or .4 mg/kg
antimycinAhadno effect on paclitaxel-inducedmechan-
ical hypersensitivity at 1, 3, or 24 hours after administra-
tion (data not shown). One hour after.6mg/kg antimycin
A administration, responses to all von Frey hairs were
significantly inhibited compared with the concurrent
vehicle-treated group (Fig 2, P < .05, 2-tailed unpaired
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t-tests with Bonferroni correction). This observed inhibi-
tion evoked by .6 mg/kg antimycin A constituted a
complete reversal of paclitaxel-induced mechanical
Figure 1. Effect of complex I inhibition on established
paclitaxel-induced mechanical hypersensitivity. (A–C) The effect
of rotenone on withdrawal responses to 4 g, 8 g, and 15 g von
Frey, respectively. Graphs show the mean 6 SEM of the number
ofwithdrawals before paclitaxel (Pre-PAC BL, n = 20), after pacli-
taxel before rotenone/vehicle (Post-PAC BL, n = 20), then 1, 3,
and 24 hours after injection of rotenone (3 mg/kg or 5 mg/kg)
or vehicle (Post-drug, n = 6–7 per group, except n = 5 at 24 hours
for 5 mg/kg rotenone). #P < .05, 1-tailed paired t-tests
comparing with pre-paclitaxel baseline responses. *P < .05, 1-
way ANOVA with Dunnett post hoc comparing with a
concurrent vehicle-treated group. In a separate experiment,
1 mg/kg and 2 mg/kg rotenone had no effect on paclitaxel-
induced mechanical hypersensitivity (data not shown).
Figure 2. Effect of complex III inhibition on established
paclitaxel-induced mechanical hypersensitivity. (A–C) The effect
of antimycin A onwithdrawal responses to 4 g, 8 g, and 15 g von
Frey, respectively. Graphs show the mean 6 SEM of the number
ofwithdrawals before paclitaxel (Pre-PAC BL, n = 16), after pacli-
taxel before rotenone/vehicle (Post-PAC BL, n = 16), then 1, 3,
and 24 hours after injection of .6 mg/kg antimycin A or vehicle
(Post-drug, n = 8 per group). #P < .05, 1-tailed paired t-tests
comparing with pre-paclitaxel baseline responses. *P < .05, 2-
tailed unpaired t-tests with Bonferroni correction comparing
with a concurrent vehicle-treated group. In a separate experi-
ment, .2 mg/kg and .4 mg/kg antimycin A had no effect on
paclitaxel-induced mechanical hypersensitivity (data not
shown).
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hypersensitivity as there was no significant difference
between post-antimycin A responses and pre-paclitaxel
responses to all von Freys (Fig 2, 2-tailed paired t-tests).
Three hours after .6 mg/kg antimycin A, therewas a small
but significant increase in responses to von Frey 4 g
compared to vehicle (Fig 2A, P < .05, 2-tailed unpaired
t-test with Bonferroni correction) but no effect on re-
sponses to von Frey 8 g and 15 g (Figs 2B and 2C). No
persistent effect of antimycin Awas observed at 24 hours
after administration, with withdrawal responses to all
von Freys returning to post-paclitaxel/pre-antimycin A
response levels.
Effect of Complex I Inhibition on
Development of Paclitaxel-Induced
Mechanical Hypersensitivity
We have previously found that scavenging ROS in vivo
not only markedly inhibited established paclitaxel-
induced mechanical hypersensitivity but could also
prevent the development of paclitaxel-induced mechan-
ical hypersensitivity.8 Given these previous findings and
the observed inhibitory effects of complex I inhibition
on paclitaxel-induced mechanical hypersensitivity, we
examined theeffectsof complex I inhibitionon thedevel-
opment of paclitaxel-induced mechanical hypersensitiv-
ity. Because of concerns regarding potential motor
effects of prolonged daily dosing with rotenone, we
limited daily dosing to 7 consecutive days. In separate ex-
periments, rotenonewasadministeredeitherondays 7 to
13 or on days 1 to 5 to examine the effects of complex I
inhibition on the development of paclitaxel-inducedme-
chanical hypersensitivity after paclitaxel therapy or
before/during paclitaxel therapy, respectively (Fig 3).
Administration of 7 daily doses of 1 or 2 mg/kg rote-
none on days 7 to 13, commencing the day after the final
injection of paclitaxel, had no significant effect on the
eventual development of paclitaxel-induced mechanical
hypersensitivity (Figs 3A–3C). Overall, from day 14
onward, significant paclitaxel-induced mechanical
hypersensitivity compared with pre-paclitaxel baseline
responses to all von Freys was observed in both the rote-
none- and vehicle-treated groups (Figs 3A–3C, P < .05,
1-way RM ANOVA with Dunnett post hoc analysis). The
exceptions to this were von Frey 4 g responses for the
vehicle-treated group at days 14 and 23, von Frey 4 g re-
sponses for the 1 mg/kg rotenone group at days 38 and
44, and von Frey 8 g responses for the 1 mg/kg rotenone
group on day 44. During the period of rotenone/vehicle
administration on days 10 and 12, responses to von Frey 4
g were not different from pre-paclitaxel baseline levels
for both the 1 mg/kg and 2 mg/kg rotenone groups,
whereas significant allodyniawas observed in the vehicle
group at day 10 (Fig 3A, P < .05, 1-way RM ANOVA with
Dunnett post hoc analysis). Similarly, responses to von
Frey 8 g were also unaltered compared with pre-
paclitaxel baseline levels in the 1 mg/kg rotenone group
on days 10 and 12, whereas significant hypersensitivity
was found in the vehicle group at day 10 (Fig 3A,
P < .05, 1-way RM ANOVA with Dunnett post hoc anal-
ysis). These effects could indicate a slight delay in the
full development of paclitaxel-induced mechanical hy-
persensitivity after rotenone treatment on days 7 to 13.
In a separate experiment, we investigated the effects
of rotenone administration before and during pacli-
taxel therapy with 7 daily doses of 2 mg/kg rotenone
on days 1 to 5 (Figs 3D–3F). This rotenone dosing
paradigm also had no significant effect on the
eventual development of paclitaxel-induced mechani-
cal hypersensitivity. From day 14 onward, both the rote-
none- and vehicle-treated groups displayed significant
mechanical hypersensitivity compared with pre-
paclitaxel baseline responses to all von Freys (Figs 3D–
3F, P < .05, 1-way RM ANOVA with Dunnett post hoc
analysis). Area under the curve analysis from day 10 on-
ward versus pre-paclitaxel baseline values confirmed no
overall significant difference in the development of
paclitaxel-induced mechanical hypersensitivity be-
tween vehicle- and rotenone-treated rats (data not
shown). However, also akin to the effects of the day 7
to 13 rotenone dosing paradigm, there was a slight
delay in the emergence of mechanical hypersensitivity
in the rotenone-treated group. Significant paclitaxel-
induced mechanical hypersensitivity was not observed
until day 14 in the rotenone-treated group compared
with day 10 in the vehicle-treated group (Figs 3D–3F).
The experimental design used here enabled the acute
nociceptive effects of rotenone to be assessed because
the first injection of rotenone was administered on
day1 and the rats were tested on day 0 before the first
paclitaxel administration. Rotenone 2 mg/kg did not
significantly alter the normal responses to von Frey
stimulation (Figs 3D–3F, day 0).
In summary, rotenone administration caused a slight
delay in the appearance of paclitaxel-induced mechani-
cal hypersensitivity but did not significantly affect the
overall development of paclitaxel-induced mechanical
hypersensitivity and its magnitude.
Effect of Complex III Inhibition on
Development of Paclitaxel-Induced
Mechanical Hypersensitivity
To compare the effects of complex III inhibition with
complex I inhibition on the development of paclitaxel-
induced mechanical hypersensitivity, we performed ex-
periments using antimycin A administered in the same
dosing paradigms used in the rotenone experiments
described previously. Administration of 7 daily doses
of .2 or .4 mg/kg antimycin A on days 7 to 13,
commencing the day after the final injection of pacli-
taxel, had no effect on the eventual development of
paclitaxel-induced mechanical hypersensitivity (Figs
4A–4C, P < .05, 1-way RM ANOVA with Dunnett post
hoc analysis). Overall, from day 23 onward, significant
paclitaxel-induced mechanical hypersensitivity
compared with pre-paclitaxel baseline responses to all
von Freys was observed in both the antimycin A- and
vehicle-treated groups (Figs 4A–4C, P < .05, 1-way RM
ANOVA with Dunnett post hoc analysis). The excep-
tions to this were von Frey 4 g responses for the
vehicle-treated group at day 28, the .2 mg/kg antimycin
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A group at days 23 and 38, and the .4 mg/kg antimycin
A group at day 23. There were significant increases in
the number of withdrawal responses to von Frey 8 g
and 15 g compared with the baseline responses before
day 23 in the time course of this experiment.
Rats treatedwith .4mg/kg antimycin A displayed signif-
icant hypersensitivity to von Frey 8 g and 15 g at days 14
and 18, whereas such effects were seen with the
vehicle-treated group on day 14 only. In addition,
both antimycin A-treated groups show significantly
increased responses to von Frey 15 g at day 10
compared with baseline responses (Fig 4C, P < .05, 1-
way RM ANOVA with Dunnett post hoc analysis). How-
ever, these effects were the only significant effects
Figure 3. Effect of complex I inhibition on the development of paclitaxel-induced mechanical hypersensitivity. All graphs show the
mean 6 SEM of the number of withdrawals to von Frey stimulation. (A–C) The effect of daily dosing of rotenone (1 mg/kg or 2 mg/kg)
on days 7 to 13 (after paclitaxel therapy), on withdrawal responses to 4 g, 8 g, and 15 g von Frey, respectively, up to day 44 after paclitaxel
initiation. (D–F) The effect of daily dosing of rotenone (2 mg/kg) on days 1 to 5 (before and during paclitaxel therapy), on withdrawal
responses to4g,8g,and15gvonFrey, respectively,uptoday44afterpaclitaxel initiation.Solid line indicates theperiodof rotenone/vehicle
administration.Arrows indicate 4 injections of 2mg/kgpaclitaxel ondays 0, 2, 4, and6. In all cases, *P< .05, 1-wayRMANOVAwithDunnett
post hoc comparing to pre-paclitaxel baseline responses indicating the occurrence of significant paclitaxel-inducedmechanical hypersen-
sitivity; n = 8 per group. (A–C) Asterisks are in the following order: Veh (upper row), 1 mg/kg Rot (center), 2 mg/kg Rot (lower). ** or ***
indicates that2or3groupsdisplay significantpaclitaxel-inducedmechanicalhypersensitivityat that timepoint.Veh,vehicle;Rot, rotenone.
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observed during the antimycin A/vehicle dosing period
from days 7 to 13.
In a separate experiment, we investigated the effects
of antimycin A administration before and during pacli-
taxel therapy with 7 daily doses of .4 mg/kg antimycin
A on days1 to 5 (Figs 4D–4F). In contrast to the previous
prophylactic dosing (days 7–13) experiment, .4 mg/kg
antimycin A significantly delayed and attenuated the
development of paclitaxel-induced mechanical hyper-
sensitivity to all von Freys (Figs 4D–4F). The expected
Figure 4. Effect of complex III inhibition on the development of paclitaxel-inducedmechanical hypersensitivity. All graphs show the
mean6 SEMof the number of withdrawals to von Frey stimulation. (A–C) The effect of daily dosing of antimycin A (.2 mg/kg or .4mg/
kg) on days 7 to 13 (after paclitaxel therapy) on withdrawal responses to 4 g, 8 g, and 15 g von Frey, respectively, up to day 44 after
paclitaxel initiation. (D–F) The effect of daily dosing of .4mg/kg antimycinA ondays1 to 5 (before andduring paclitaxel therapy), on
withdrawal responses to 4 g, 8 g, and 15 g von Frey, respectively, up to day 44 after paclitaxel initiation. Solid line indicates periods of
antimycin A/vehicle administration. Arrows indicate 4 injections of 2 mg/kg paclitaxel on days 0, 2, 4, and 6. #P < .05, 1-tailed paired t-
tests compared with baseline responses demonstrating acute pronociceptive effects of antimycin A on normal mechanical responses.
In all cases, *P < .05, 1-way repeated measures ANOVAwith Dunnett post hoc comparing with pre-paclitaxel baseline responses indi-
cating the occurrence of significant paclitaxel-induced mechanical hypersensitivity; n = 9 to 14 per group. (A–C) Asterisks are in the
following order: Veh (upper row), .2 mg/kg AA (center), .4 mg/kg AA (lower). ** or *** indicates that 2 or 3 groups display significant
paclitaxel-induced mechanical hypersensitivity at that time point. Inserts (D–F) show the area under curve analysis of responses at
baseline and on days 10 to 44. *P < .05 1-tailed unpaired t-tests. n = 9–14 per group. Veh, vehicle; AA, antimycin A.
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significant increase in withdrawal responses to all von
Freys compared with the pre-paclitaxel baseline levels
was observed in the vehicle-treated group from day 10
onward (Figs 4D–4F, P < .05, 1-way RMANOVAwith Dun-
nett post hoc analysis). In comparison, von Frey 4 g re-
sponses were only significantly increased on day 33,
and von Frey 8 g responses were significantly increased
from day 28 onward in the antimycin A-treated group
(Figs 4D and 4E, P < .05, 1-way RM ANOVAwith Dunnett
post hoc analysis). Responses to von Frey 15 g in the anti-
mycin A group were less than those observed in the
vehicle group but were significantly increased compared
with their pre-paclitaxel baseline (Fig 4F, P < .05, 1-way
RM ANOVA with Dunnett post hoc analysis). Area under
the curve analysis from day 10 onward versus pre-
paclitaxel baseline values confirmed a significant overall
difference between antimycin A- and vehicle-treated
rats in the development of paclitaxel-induced mechani-
cal hypersensitivity to all von Freys (Figs 4D–4F inserts,
P < .05, 1-tailed paired t-tests). The experimental design
used here enabled the acute nociceptive effects of anti-
mycin A to be assessed because the first injection of anti-
mycin A was administered on day 1 and the rats were
tested on day 0 before the first paclitaxel administration.
A single injection of .4 mg/kg antimycin A resulted in a
significant mechanical hypersensitivity to all von Freys
compared with baseline response levels (Figs 4D–4F,
P < .05, 1-tailed paired t-tests).
In summary, antimycin A administration before and
during paclitaxel therapy significantly attenuated the
overall development of paclitaxel-induced mechanical
hypersensitivity. However, antimycin A administration
after paclitaxel therapy did not significantly alter
the development of paclitaxel-induced mechanical hy-
persensitivity. In addition, antimycin A significantly
increased normal baseline responses to von Frey stimu-
lation, suggesting a differential effect of antimycin A
administration in naive versus paclitaxel-treated rats.
Effect of Complex Inhibitors on Motor
Function
Since rotenone is used to induce Parkinsonian symp-
toms,4we examined if the doses of rotenone and antimy-
cin A used in our behavioral studies had any deleterious
effects on motor function, which could therefore poten-
tially affect withdrawal responses to von Frey stimula-
tion. A single dose of .6 mg/kg antimycin A did not
affect performance on an accelerating Rota-rod at 1, 3,
or 24 hours after administration in naive rats (Fig 5A).
Figure 5. Effect of complex I or III inhibition on motor function in naive rats. All graphs show the mean 6 SEM of responses. (A, B)
The effects of high dose rotenone (5 mg/kg) and antimycin A (.6 mg/kg) on accelerating Rota-rod and catalepsy ring latencies,
respectively, before (n = 18), then 1, 3, and 24 hours after administration (n = 6 per group). *P < .05, 1-way ANOVA with Dunnett
post hoc comparing with the concurrent vehicle-treated group. In a separate experiment, 3 mg/kg rotenone had no effect on accel-
erating Rota-rod latencies compared with vehicle treatment (data not shown). (C, D) The effect of daily dosing of 2 mg/kg rotenone
and .4 mg/kg antimycin A on days 1 to 5 on accelerating Rota-rod and catalepsy ring latencies, respectively, up to day 44 after
paclitaxel initiation. Solid lines indicate periods of complex inhibitor/vehicle administration. Arrows indicate 4 injections
of 2 mg/kg paclitaxel on days 0, 2, 4, and 6. n = 22 for vehicle, n = 9 for antimycin A, and n = 8 for rotenone. Veh, vehicle; AA,
antimycin A; Rot, rotenone.
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A single dose of 5 mg/kg rotenone significantly reduced
latencies at 3 hours and 24 hours after administration of
rotenone but had no such effect at 1 hour compared
with the concurrent vehicle-treated group (Fig 5A,
P < .05, 1-way ANOVA with Dunnett post hoc analysis).
In a similar separate experiment, a single dose of 3 mg/
kg rotenone had no effect on accelerating Rota-rod per-
formance at 1, 3, or 24 hours after administration in
naive rats compared with a concurrent vehicle-treated
group (data not shown). Therefore, rotenone can affect
motor coordination when administered as a single dose
of 5 mg/kg but with a delay of 3 hours until onset.
In addition to the Rota-rod test ofmotor coordination,
we assessed for drug-induced catalepsy after single doses
of antimycin A and rotenone. Neither .6mg/kg antimycin
nor 5 mg/kg rotenone had any significant effect on the
time spent immobile on a catalepsy ring at 1, 3, or
24 hours after administration in naive rats (Fig 5B). The
larger mean latency and SEM for the 5 mg/kg rotenone
group at the 24-hour time point was because 1 of the 6
rats remained on the ring for 30 seconds. Thus, the effect
at 24 hours after administration was somewhat skewed
by the response of this one rat. In a similar separate
experiment, a single dose of 3mg/kg rotenone hadno ef-
fect on the time spent immobile on a catalepsy ring at 1,
3, or 24 hours after administration in naive rats
compared with a concurrent vehicle-treated group
(data not shown).
We also assessed whether 7 daily injections of either
rotenone or antimycin A affected motor function as
used in the prophylactic dosing paradigms described
earlier. Neither .4 mg/kg antimycin A nor 2 mg/kg rote-
none (administered days 1 to 5 inclusive) had any
significant effect on accelerating Rota-rod performance
(Fig 5C) or time spent immobile on a catalepsy ring
(Fig 5D) for the duration of the experiments.
Discussion
In a series of pharmacological behavioral studies, we
have assessed the effects of mitochondrial complex I or
complex III inhibition on established paclitaxel-induced
mechanical hypersensitivity and the development of
this painful condition. Inhibition of complex I or complex
III at different time points of the paclitaxel-induced pain
syndrome had differential effects (discussed below) and
provides further evidence of paclitaxel-induced mito-
chondrial dysfunction in vivo.
Complex I inhibition, with systemic administration of
the maximally tolerated dose of rotenone (5 mg/kg),
inhibited established paclitaxel-induced mechanical hy-
persensitivity at 1, 3, and 24 hours after administration.
However, deleterious effects on motor coordination
were also observed with this dose at 3 and 24 hours af-
ter administration. A lower dose of 3 mg/kg rotenone
attenuated established paclitaxel-induced mechanical
hypersensitivity at 3 hours after administration without
any impairment of motor coordination. Complex III in-
hibition with systemic administration of the maximally
tolerated dose of antimycin A (.6 mg/kg) reversed estab-
lished paclitaxel-induced mechanical hypersensitivity at
1 hour after administration. This dose of antimycin A
had no effect on motor coordination. Therefore, it
seems that inhibition of complex I or III can reverse or
attenuate established paclitaxel-induced mechanical
hypersensitivity, but with the caveat that some of the
effects seen after complex I inhibition may be attrib-
uted to adverse effects of motor coordination. Other
studies have examined the effects of pharmacological
inhibition of complex I or III on chemotherapy-
induced pain behaviors assessed by paw pressure18 or
von Frey stimulation.47 Peripheral administration of
rotenone, by intradermal injection, significantly attenu-
ated vincristine-induced mechanical hyperalgesia.
Similar to the effects of rotenone reported here, rote-
none attenuated vincristine-induced mechanical hyper-
algesia for up to 3 hours in a dose-related manner.18
These authors also showed that peripheral administra-
tion of antimycin A significantly attenuated
vincristine-induced mechanical hyperalgesia. In addi-
tion, the effects of peripheral antimycin A were dose
related and lasted for 1 hour, as also observed in our
study. In contrast to our findings, after systemic rote-
none administration, enhancement (20–25% approxi-
mately) of paclitaxel- and oxaliplatin-induced
mechanical hypersensitivity has been reported.47 How-
ever, these facilitatory effects on mechanical hypersensi-
tivity were observed at 30 minutes after administration,
whereas our inhibitory effects of rotenone were
observed at 1 and 3 hours after administration.
In prophylactic studies, rotenone or antimycin A was
administered daily for a week, either after paclitaxel
administration (days 7–13) or before and during pacli-
taxel administration (days 1 to 5), to establish the
effects of complex I or III inhibition on the development
of paclitaxel-induced mechanical hypersensitivity.
Rotenone had no effect on the development of
paclitaxel-induced mechanical hypersensitivity in either
prophylactic dosing paradigm. Antimycin A had no ef-
fect on the development of paclitaxel-induced mechan-
ical hypersensitivity when administered after paclitaxel.
In contrast, antimycin A significantly prevented the
development of paclitaxel-induced mechanical hyper-
sensitivity when administered before and during pacli-
taxel administration. These antinociceptive effects of
antimycin A were not accompanied by any motor
impairment. Therefore, only complex III inhibition, not
complex I inhibition, can significantly prevent the emer-
gence of paclitaxel-induced pain provided that complex
III is inhibited before and during the exposure to pacli-
taxel.
A single injection of antimycin A in naive rats resulted
in a significant increase in the withdrawal responses to
von Frey stimulation, suggesting that complex III inhibi-
tion is normally pronociceptive. Increased withdrawal
responses to von Frey stimulation have also been
reported in naive mice after a single intrathecal admin-
istration of antimycin A.24 In comparison, we found
that systemic rotenone did not alter withdrawal re-
sponses to von Frey stimulation in naive rats. These
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observations are also in agreement with previously pub-
lished findings.18,47 The switch in the behavioral effects
of antimycin A from pronociceptive under normal con-
ditions to antinociceptive after paclitaxel further dem-
onstrates that paclitaxel causes mitochondrial
dysfunction in vivo because the behavioral conse-
quences of complex III inhibition differ. Furthermore,
it suggests that the precise means by which mitochon-
drial ROS and its modulation affects pain behavior is
likely to be dependent on neuronal status. In addition,
the lack of effect of antimycin A on the development of
paclitaxel-induced pain when administered after pacli-
taxel (days 7–13) may not indicate a lack of activity
per se, as one would expect a facilitatory effect under
normal conditions, but it may indicate that complex III
inhibition following paclitaxel is not sufficient to coun-
teract the mitochondrial effects of paclitaxel already
initiated that are causal to the development of
paclitaxel-induced pain. We did observe a reversal of es-
tablished paclitaxel-induced mechanical hypersensitivity
1 hour following a higher dose of antimycin A, further
indicating the contribution of mitochondrial dysfunc-
tion to the maintenance of paclitaxel-induced pain.
Our main hypothesis is that paclitaxel results in an in-
crease in ROS due to mitochondrial dysfunction, and
this hypothesis is supported by evidence from studies us-
ing ROS scavengers. Previous work has shown that
phenyl N-tert-butylnitrone, a nonspecific ROS scavenger,
can attenuate the development of paclitaxel-induced
mechanical hypersensitivity.8,23 In one study, the
authors looked at whether the timing of ROS
scavenger administration was important to the
outcome. The results reveal that ROS scavenging on
days 0 to 7, ie, at the same time as paclitaxel
administration, had no effect on the development of
pain, whereas if paclitaxel was given on days 7 to 15,
development of pain was attenuated.23 This suggests
that the period between the last injection of paclitaxel
and the time of normal onset of pain is a crucial window
in which ROS scavenging can be effective. Here, we find
that complex III inhibitionwith antimycin Awas effective
when administered on days 1 to 5 but not on days 7 to
13. Collectively, this could suggest that paclitaxel causes
mitochondrial dysfunction following administration
but that it takes time for the effects of excessive ROS to
accumulate and go beyond the capacity of endogenous
antioxidant systems to result in ROS-driven pain behav-
iors. Such effects may underlie the coasting phenome-
non seen after paclitaxel. Our data also show that
modulation of mitochondria during paclitaxel exposure
produces long-lasting beneficial effects; for example,
the inhibitory effects of antimycin A administration on
day 1 to day 5 are observed up to day 28. These data
further suggest that early mitochondrial dysfunction in
neurons is a key initiator of paclitaxel-induced painful
neuropathy.
The role of ROS has been demonstrated in various
other models of acute pain and chronic pain evoked by
either inflammation or nerve injury.16,21,22,26,31,39,40
The effects of pharmacological modulation of the
mitochondrial electron transport chain on pain
behavior and ROS levels in sensory neurons have also
been demonstrated.25 Pretreatment with intrathecal
rotenone markedly inhibited N-methyl-D-aspartate–
evoked mechanical hypersensitivity and prevented
N-methyl-D-aspartate–evoked increases in mitochon-
drial superoxide levels in the superficial and deep dorsal
horns of the spinal cord.25 A substantial body of evidence
has shown that ion channels in sensory neurons can be
regulated by ROS and reactive nitrogen species (for a
recent review, see Gamper and Ooi14). By extension, as
mitochondria are a major source of ROS, their dysfunc-
tion may well play a role in neuronal regulation and
excitability. In isolated dorsal root ganglion neurons,
oxidation of M-type potassium channels increased cur-
rents and thus suppressed neuronal excitability.27 In com-
parison, oxidation of T-type calcium channels decreased
currents in dorsal root ganglion neurons, also suppress-
ing neuronal excitability.42 In addition, oxidation of
T-type calcium channels was associatedwith antinocicep-
tive effects in vivo.42 In contrast, other channels such as
TRPA1 have been shown to be activated by ROS in dorsal
root ganglion neurons, leading to neuronal excitability
and pain behaviors.2 Although not performed in sensory
neurons, two other studies using slice preparations from
different brain regions have demonstrated interesting
effects of pharmacological modulation of the mitochon-
drial electron transport chain that could be of relevance
to our data. First, in cortical pyramidal neurons, antimy-
cin A, at a concentration shown to inhibit complex III ac-
tivity by 20%, reduced voltage-gated calcium currents
by 50%.46 Second, in cerebellar stellate cells, antimycin
A, and to a lesser extent rotenone, increased the fre-
quency of miniature inhibitory postsynaptic currents
via recruitment of a3-containing g-aminobutyricacidA re-
ceptors.1 Therefore, it could be hypothesized that a
decrease in voltage-gated calcium currents and/or in-
crease in inhibitory tone at sensory synapses could under-
pin the antinociceptive effects of antimycin A on
paclitaxel-induced mechanical hypersensitivity reported
here.
In summary, we have presented the consequences of
pharmacological modulation of mitochondrial ROS-
producing sites, complex I and complex III, on
paclitaxel-induced pain behavior. Only inhibition of
complex III produced antinociceptive effects on both
the development and maintenance of paclitaxel-
induced pain. These studies provide further evidence of
paclitaxel-evoked mitochondrial dysfunction in sensory
neurons in vivo and suggest that complex III activity in
particular is instrumental in this pain state.
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